Sorel, N <br/><br/>
Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia.  [electronic resource] 

 -  Biochemical and biophysical research communications  Oct 2004 
 - 728-30 p.  digital 
<br/><br/> Publication Type: Comparative Study; Evaluation Study; Journal Article 
<br/><br/><label>ISSN: </label>0006-291X 
<br/><br/><label>Standard No.: </label>10.1016/j.bbrc.2004.08.169  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--administration & dosage<br/>Benzamides<br/>Cell Differentiation--drug effects<br/>Cells, Cultured<br/>Drug Resistance--genetics<br/>Enzyme Inhibitors--administration & dosage<br/>Fusion Proteins, bcr-abl--genetics<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Genetic Predisposition to Disease--genetics<br/>Genetic Testing--methods<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Mutation<br/>Phosphotransferases--antagonists & inhibitors<br/>Piperazines--administration & dosage<br/>Protein Structure, Tertiary<br/>Pyrimidines--administration & dosage<br/>Sequence Analysis, Protein<br/>Stem Cells--drug effects<br/>Structure-Activity Relationship<br/>Tumor Cells, Cultured